Filter Results:
(605)
Show Results For
- All HBS Web
(1,032)
- People (4)
- News (249)
- Research (605)
- Events (7)
- Multimedia (24)
- Faculty Publications (398)
Show Results For
- All HBS Web
(1,032)
- People (4)
- News (249)
- Research (605)
- Events (7)
- Multimedia (24)
- Faculty Publications (398)
Sort by
- 01 Aug 2017
- First Look
First Look at New Research and Ideas, August 1
Scott Morton, Fiona, Ariel Dora Stern, and Scott Stern Abstract—Biologic drugs (therapeutic proteins or “large-molecule drugs”) represent a substantial and growing share of the U.S. drug market, accounting... View Details
Keywords: Sean Silverthorne
- 12 Jul 2020
- Research & Ideas
Solving COVID'S Mental Health Crisis
for everyone and also highlighted the important link between research, discovery, and cure." The GPP is a statewide prevention program aimed at reducing the use of dangerous drugs among teens and young adults through awareness campaigns,... View Details
- 10 Oct 2017
- First Look
First Look at New Research and Ideas, October 10, 2017
in the diabetic space, became MannKind’s marketing partner and helped launch Afrezza in February, 2015. Although the drug had a black box warning and required doctors to perform a lung test on patients, expectations were high, with some... View Details
Keywords: Sean Silverthorne
- 09 Aug 2016
- First Look
August 9, 2016
https://www.hbs.edu/faculty/Pages/item.aspx?num=51304 The Impact of the Entry of Biosimilars: Evidence from Europe By: Scott Morton, Fiona, Ariel Dora Stern, and Scott Stern Abstract—Biologic drugs (therapeutic proteins or... View Details
Keywords: Sean Silverthorne
- 23 Mar 2010
- First Look
First Look: March 23
Publications "From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance Author: Arthur A. Daemmrich Publication: Chap. 13 in The Fragmentation of U.S. Health Care, Oxford University Press, 2010 Abstract Adverse View Details
Keywords: Martha Lagace
- 27 Jun 2005
- Research & Ideas
The Potential Downside of Win-Win
consideration for all managers. Value Creation—and Collusion Suppose that pharmaceutical firm A manufactures a new, beneficial drug and begins selling 100 million pills per year at $3.05 per pill. Each pill costs 5 cents to manufacture,... View Details
Keywords: by Max H. Bazerman
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
South Africa over its attempt to reduce the cost of HIV drugs through parallel importation (buying pharmaceuticals in countries with lower prices and then importing them) and compulsory licensing (requiring patent holders to allow others... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman
- 30 May 2007
- Research & Ideas
Health Care Under a Research Microscope
Cambridge, Massachusetts, and you will likely be administered beta blockers, a class of drug that's generally recommended after a heart attack. The rate at which that drug is delivered nationwide, however,... View Details
- 08 Apr 2009
- Research & Ideas
Clayton Christensen on Disrupting Health Care
screening participants in drug trials and make it possible to track and troubleshoot unexpected problems that show up after a drug is introduced into the general population, like what happened with Vioxx.... View Details
- 19 Sep 2017
- First Look
First Look at New Research and Ideas, September 19
time, Imprimis was in the process of seeking FDA approval for a branded drug called Impracor. This process, already difficult, was further complicated by recent manufacturing issues. Meanwhile, the opportunity arose for Imprimis to... View Details
Keywords: Sean Silverthorne
- 23 Apr 2014
- HBS Case
Are Electronic Cigarettes a Public Good or Health Hazard?
Drug Administration is proposing the first federal oversight of the product. The very fact users could control the amount of nicotine they ingested led to worry that e-cigarettes would cause smokers to take in more nicotine, rather than... View Details
- 11 Aug 2003
- Research & Ideas
Cheap, Fast, and In Control: How Tech Aids Innovation
experimentation and are triggering fundamental changes in R&D processes and performance in such fields as integrated circuit design, automotive development, and pharmaceutical drug discovery. Computer modeling and simulation, rapid... View Details
Keywords: by Wendy Guild
- 12 Jan 2016
- First Look
January 12, 2016
November–December 2015 Operations Research Active Postmarketing Drug Surveillance for Multiple Adverse Events By: Goh, Joel, Margrét V. Bjarnadóttir, Mohsen Bayati, and Stefanos A. Zenios Abstract—Postmarketing View Details
Keywords: Carmen Nobel
- 09 Apr 2012
- Research & Ideas
Who Sways the USDA on GMO Approvals?
Other Agencies Influence Approvals In the case of procedural legitimacy, the researchers found a strong influence from an unlikely source—the USDA's sister agency, the Food and Drug Administration. In the process of approving GMOs,... View Details
- 12 Apr 2018
- Op-Ed
Op-Ed: The Trouble with Tariffs
active ingredients for anti-nausea drugs, even the drug inside an EpiPen. There were also more mundane items like milking machine parts and telescopic gunsights for rifles. The careful selection avoided high-profile items like smartphones... View Details
Keywords: by Willy C. Shih; Manufacturing; Auto; Steel; Air Transportation; Technology; Telecommunications
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
benefits of sharing data, which can then be used to more quickly identify the most pressing targets and design trials to address them. Innovations to the typical clinical trial model are also being used. In an adaptive platform trial, for example, different View Details
- 10 Sep 2008
- Research & Ideas
Long-Tail Economics? Give Me Blockbusters!
by focusing on bigger films that require a bigger commitment." Jeff Robinov believes in blockbusters and his strategy is to create more of them. The pharmaceutical and entertainment industries are similar. R&D costs in both are high. Results are unpredictable.... View Details
- 12 Feb 2019
- First Look
New Research and Ideas, February 12, 2019
Devices: Challenges and Opportunities for U.S. Regulators and Innovators By: Gordon, William J., and Ariel Dora Stern Abstract— Software has become an increasingly important component of medical device technology. Through legislation like the 21st Century Cures Act as... View Details
Keywords: Dina Gerdeman
- 08 Mar 2016
- First Look
March 8, 2016
cultural model and undermine their own positions with inappropriate use of symbolic market-creation actions. Download working paper: https://www.hbs.edu/faculty/Pages/item.aspx?num=50701 Harvard Business School Case 916-026 Express Scripts: Promoting Prescription View Details
Keywords: Sean Silverthorne
- 18 Aug 2017
- Op-Ed
Op-Ed: Courageous Leader Triggers a Moral Revolt of CEOs Against Trump
actions was not without risk for the CEOs and their companies” While many CEOs prefer to stay under the radar and avoid public scrutiny, Ken Frazier led the way with his example. As the chair of PhRMA, the pharmaceutical manufacturers association, Frazier has led the... View Details
Keywords: by Bill George